

**PRELIMINARY AMENDMENT**

**In the Specification:**

On page 46, lines 7-8, please replace "Guo et al., Nature Medicine, vol. 4:1-5, (April, 1997)" with "--Guo et al., Nature Medicine, vol. 3:451-455, (April, 1997)--" to correct typographical errors.

A copy of Guo et al. has been submitted to the patent office in a Supplemental Information Disclosure Statement on January 9, 1998.

**In the Claims:**

Please cancel claims 23-32 without prejudice to further prosecution thereof and amend claims 1, 18, 33, 36, 39, 42, and 45 as follows:

1. (Amended) An immunogenic composition [for administration to] useful for treating a patient mammal having diseased cells, comprising:

(a) an isolated autologous target diseased cell which expresses one or more primary and costimulatory T cell activation molecules at a level higher than that in said diseased cells in said patient mammal; and

(b) a bridge molecule comprising one or more binding sites for one or more costimulatory molecules on the surface of T cells in said patient mammal, wherein said bridge molecule is attached to said target diseased cell.